Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.

Daniel A. Pollyea,Tracy I. George,Kathryn Foucar,Harry P. Erba,Michael A. Thompson,Mehrdad Abedi,Gail J. Roboz,Danny Landau,John M. Pagel,Karen Seiter,Christopher R. Cogle,Melissa Nifenecker,Arlene S. Swern,Pavel Kiselev,Mary M. Sugrue

Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.

2017

Daniel A. Pollyea
Tracy I. George
Kathryn Foucar
Harry P. Erba
Michael A. Thompson
Mehrdad Abedi
Gail J. Roboz
Danny Landau
John M. Pagel
Karen Seiter
Christopher R. Cogle
Melissa Nifenecker
Arlene S. Swern
Pavel Kiselev
Mary M. Sugrue

7022Background: Recurrent mutations in AML-associated genes have prognostic value and may help guide treatment decisions. Molecular genetic testing patterns for AML in clinical practice are largely...

Keywords:

Disease registry
Pathology
Myeloid leukemia
Genetic testing
Medicine
newly diagnosed
treatment decision making
Oncology
molecular genetic testing
Clinical Practice
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations